# 153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer

> **NCT00450619** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 44 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **RADIATION:** Samarium Sm 153 lexidronam pentasodium
- **BIOLOGICAL:** Sargramostim
- **BIOLOGICAL:** Recombinant vaccinia-TRICOM vaccine
- **BIOLOGICAL:** Recombinant fowlpox-TRICOM vaccine

## Key facts

- **NCT ID:** NCT00450619
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2017-01-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00450619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00450619, "153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00450619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*